Advance on the application of the low concentration atropine for the prevention and control of myopia in children

doi:10.3877/cma.j.issn.2095-2007.2023.02.012

Abstract

Abstract:

Myopia is a global problem that is growing at an epidemic rate in the worldwide. In addition to the burden of conventional treatment, high myopia is more likely to lead to vision-threatening complications. Controlling the onset and development of myopia in children can reduce the risk of developing the disease associated with high myopia. The development of myopia can be slowed by a variety of optical, environmental, and pharmaceutical strategies, of which atropine has been shown to be effective. The documents at home and abroad in recent years about the mechanism of action, timing of use, effectiveness, safety, adverse reactions, withdrawal reactions, and combined treatment plans of low concentration atropine in the control of myopia in children were reviewed in this paper, which could provide a basis for its widely clinical application.

Key words: Low concentration atropine, Myopia, Efficacy, Safety

Yan Zhao, Dan Zhu. Advance on the application of the low concentration atropine for the prevention and control of myopia in children[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2023, 13(02): 124-128.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2023.02.012

https://zhykyxzz.cma-cmc.com.cn/EN/Y2023/V13/I02/124

Figures/Tables 1

References 56

[14]	Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2－year randomised clinical trial[J]. Br J Ophthalmol, 2020, 104(3): 363－368.
[15]	Ford KJ, Feller MB. Assembly and disassembly of a retinal cholinergic network[J]. Vis Neurosci, 2012, 29(1): 61－71.
[16]	Raviola E, Wiesel TN. An animal model of myopia[J]. N Engl J Med, 1985, 312(25): 1609－1615.
[17]	Mcbrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism[J]. Invest Ophthalmol Vis Sci, 1993, 34(1): 205－215.
[18]	Schaeffel F, Troilo D, Wallman J, et al. Developing eyes that lack accommodation grow to compensate for imposed defocus[J]. Vis Neurosci, 1990, 4(2): 177－183.
[19]	Troilo D, Gottlieb MD, Wallman J. Visual deprivation causes myopia in chicks with optic nerve section[J]. Curr Eye Res, 1987, 6(8): 993－999.
[20]	Nebbioso M, Plateroti AM, Pucci B, et al. Role of the dopaminergic system in the development of myopia in children and adolescents[J]. J Child Neurol, 2014, 29(12): 1739－1746.
[21]	Schwahn HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick [J]. Vis Neurosci, 2000, 17(2): 165－176.
[22]	Nickla DL, Totonelly K, Dhillon B. Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks[J]. Exp Eye Res, 2010, 91(5): 715－720.
[23]	Barathi VA, Chaurasia SS, Poidinger M, et al. Involvement of GABA transporters in atropine－treated myopic retina as revealed by iTRAQ quantitative proteomics[J]. J Proteome Res, 2014, 13(11): 4647－4658.
[24]	Fischer AJ, Miethke P, Morgan IG, et al. Cholinergic amacrine cells are not required for the progression and atropine－mediated suppression of form－deprivation myopia[J]. Brain Res, 1998, 794(1): 48－60.
[25]	Lind GJ, Chew SJ, Marzani D, et al. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes[J]. Invest Ophthalmol Vis Sci, 1998, 39(12): 2217－2231.
[26]	Barathi VA, Beuerman RW. Molecular mechanisms of muscarinic receptors in mouse scleral fibroblasts: Prior to and after induction of experimental myopia with atropine treatment[J]. Mol Vis, 2011, 17: 680－692.
[27]	Christian PG, Harkin DG, Rayner C, et al. Comparative effects of posterior eye cup tissues from myopic and hyperopic chick eyes on cultured scleral fibroblasts[J]. Exp Eye Res, 2013, 107: 11－20.
[28]	Nickla DL, Zhu X, Wallman J. Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning[J]. Ophthalmic Physiol Opt, 2013, 33(3): 245－256.
[29]	Chiang ST, Phillips JR. Effect of atropine eye drops on choroidal thinning induced by hyperopic retinal defocus[J]. J Ophthalmol, 2018, PMID: 8528315.
[30]	Polak K, Polska E, Luksch A, et al. Choroidal blood flow and arterial blood pressure[J]. Eye, 2003, 17(1): 84－88.
[31]	Chua WH, Balakrishnan V, Chan YH, et al. Atropine for the treatment of childhood myopia[J]. Ophthalmology, 2006, 113(12): 2285－2291.
[32]	Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)[J]. Ophthalmology, 2012, 119(2): 347－354.
[33]	Chia A, Lu QS, Tan D. Five－year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eye drops[J]. Ophthalmology, 2016, 123(2): 391－399.
[34]	Gong Q, Janowski M, Luo M, et al. Efficacy and adverse effects of atropine in childhood myopia: a meta－analysis[J]. JAMA Ophthalmol, 2017, 135(6): 624－630.
[35]	Sacchi M, Serafino M, Villani E, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients[J]. Acta Ophthalmol, 2019, 97(8): e1136－e1140.
[36]	Wei S, Li SM, An W, et al. Safety and efficacy of low－dose atropine eyedrops for the treatment of myopia progression in Chinese children: A Randomized Clinical Trial[J]. JAMA Ophthalmol, 2020, 138(11): 1178－1184.
[37]	王卫群，钟梅，吕勇. 质量分数0.01%和0.02%阿托品滴眼液对近视儿童瞳孔直径和调节幅度影响的一年随机、双盲、临床对照试验[J]. 中华实验眼科杂志，2019，37(7)：540－545.
[38]	Brodstein RS, Brodstein DE, Olson RJ, et al. The treatment of myopia with atropine and bifocals. A long－term prospective study [J]. Ophthalmology, 1984, 91(11): 1373－1379.
[39]	Shih YF, Hsiao CK, Chen CJ, et al. An intervention trial on efficacy of atropine and multi－focal glasses in controlling myopic progression[J]. Acta Ophthalmol Scand, 2001, 79(3): 233－236.
[40]	Yi S, Huang Y, Yu SZ, et al. Therapeutic effect of atropine 1% in children with low myopia[J]. J aapos, 2015, 19(5): 426－429.
[41]	Wang YR, Bian HL, Wang Q. Atropine 0.5% eyedrops for the treatment of children with low myopia: A randomized controlled trial[J]. Medicine (Baltimore), 2017, 96(27): e7371.
[42]	Chiang MF, Kouzis A, Pointer RW, et al. Treatment of childhood myopia with atropine eyedrops and bifocal spectacles[J]. Binocul Vis Strabismus Q, 2001, 16(3): 209－215.
[43]	Kennedy RH, Dyer JA, Kennedy MA, et al. Reducing the progression of myopia with atropine: a long term cohort study of Olmsted County students[J]. Binocul Vis Strabismus Q, 2000, 15(3S): 281－304.
[44]	Syniuta LA, Isenberg SJ. Atropine and bifocals can slow the progression of myopia in children[J]. Binocul Vis Strabismus Q, 2001, 16(3): 203－208.
[45]	Yen MY, Liu JH, Kao SC, et al. Comparison of the effect of atropine and cyclopentolate on myopia [J]. Ann Ophthalmol, 1989, 21(5): 1800－1802，1807.
[1]	Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050[J]. Ophthalmology, 2016, 123(5): 1036－1042.
[2]	Buch H, Vinding T, La－Cour M, et al. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study[J]. Ophthalmology, 2004, 111(1): 53－61.
[3]	Klaver CC, Wolfs RC, Vingerling JR, et al. Age－specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study[J]. Arch Ophthalmol, 1998, 116(5): 653－658.
[4]	Iwase A, Araie M, Tomidokoro A, et al. Prevalence and causes of low vision and blindness in a Japanese adult population: the Tajimi Study[J]. Ophthalmology, 2006, 113(8): 1354－1362.
[5]	Jonas JB, Weber P, Nagaoka N, et al. Glaucoma in high myopia and parapapillary delta zone[J]. PLoS One, 2017, 12(4): e0175120.
[6]	Smith TS, Frick KD, Holden BA, et al. Potential lost productivity resulting from the global burden of uncorrected refractive error[J]. Bull World Health Organ, 2009, 87(6): 431－437.
[7]	Yam JC, Jiang Y, Tang SM, et al. Low－Concentration Atropine for Myopia Progression (LAMP) Study: a randomized, double－blinded, placebo－controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control[J]. Ophthalmology, 2019, 126(1): 113－124.
[8]	Morgan I, Rose K. How genetic is school myopia？[J]. Prog Retin Eye Res, 2005, 24(1): 1－38.
[9]	Wu PC, Tsai CL, Wu HL, et al. Outdoor activity during class recess reduces myopia onset and progression in school children[J]. Ophthalmology, 2013, 120(5): 1080－1085.
[10]	Rahi JS, Cumberland PM, Peckham CS. Myopia over the lifecourse: prevalence and early life influences in the 1958 British birth cohort[J]. Ophthalmology, 2011, 118(5): 797－804.
[11]	Lim HT, Yoon JS, Hwang SS, et al. Prevalence and associated sociodemographic factors of myopia in Korean children: the 2005 third Korea National Health and Nutrition Examination Survey (KNHANES Ⅲ)[J]. Jpn J Ophthalmol, 2012, 56(1): 76－81.
[12]	Wu PC, Chen CT, Lin KK, et al. Myopia prevention and outdoor light intensity in a school－based cluster randomized trial[J]. Ophthalmology, 2018, 125(8): 1239－1250.
[13]	Kanda H, Oshika T, Hiraoka T, et al. Effect of spectacle lenses designed to reduce relative peripheral hyperopia on myopia progression in Japanese children: a 2－year multicenter randomized controlled trial[J]. Jpn J Ophthalmol, 2018, 62(5): 537－543.
[46]	Chia A, Li W, Tan D, et al. Full－field electroretinogram findings in children in the atropine treatment for myopia (ATOM2) study[J]. Doc Ophthalmol, 2013, 126(3): 177－186.
[47]	Mcbrien NA, Stell WK, Carr B. How does atropine exert its anti－myopia effects？[J]. Ophthalmic Physiol Opt, 2013, 33(3): 373－378.
[48]	Cho WH, Fang PC, Yu HJ, et al. Analysis of tear film spatial instability for pediatric myopia under treatment[J]. Sci Rep, 2020, 10(1): e14789.
[49]	肖启国，刘祖国，张梅，等. 局部滴用阿托品建立兔干眼模型的评价 [J]. 眼科研究，2005，23(4): 340－343.
[50]	Wen Q, Fan TJ, Tian CL. Cytotoxicity of atropine to human corneal endothelial cells by inducing mitochondrion－dependent apoptosis [J]. Exp Biol Med (Maywood), 2016, 241(13): 1457－1465.
[51]	Tong L, Huang XL, Koh AL, et al. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine[J]. Ophthalmology, 2009, 116(3): 572－579.
[52]	Chia A, Chua WH, Wen L, et al. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5% [J]. Am J Ophthalmol, 2014, 157(2): 451－457.
[53]	Lu B, Congdon N, Liu X, et al. Associations between near work, outdoor activity, and myopia among adolescent students in rural China: the Xichang Pediatric Refractive Error Study report no. 2[J]. Arch Ophthalmol, 2009, 127(6): 769－775.
[54]	Si JK, Tang K, Bi HS, et al. Orthokeratology for myopia control: a meta－analysis[J]. Optom Vis Sci, 2015, 92(3): 252－257.
[55]	Janowski M, Bulte JW, Handa JT, et al. Concise review: using stem cells to prevent the progression of myopia——a concept [J]. Stem Cells, 2015, 33(7): 2104－2113.
[56]	郑玮. 卡替洛尔联合阿托品在青少年近视治疗中的作用分析 [J]. 沈阳药科大学学报，2021，38(S2)：63.

作者	地区	样本量	年龄	屈光度(D)	治疗时间(个月)	阿托品浓度(%)	对照组	结局指标
Yam等^[7]	中国香港	438	4~12	≤－1.00	12	0.05、0.025及0.01	安慰剂	眼轴长度、屈光度、调节幅度、视力及瞳孔直径
Chua等^[31]	新加坡	400	6~12	－1.00~－6.00	24	1.0	安慰剂	眼轴长度和屈光度
Chia等^[32]	新加坡	400	6~12	≤－2.00	24	0.5、0.1及0.01	安慰剂	眼轴长度、屈光度、调节幅度及视力
Chia等^[33]	新加坡	400	9~15	≤－2.50	24	0.01	安慰剂	眼轴长度、屈光力、瞳孔直径、调节幅度及视力
Sacchi等^[35]	欧洲	52	5~16	进展>0.50/年	12	0.01	安慰剂	眼轴长度、屈光度及视力
Wei等^[36]	中国	220	6~12	－1.00~－6.00	12	0.01	安慰剂	眼轴长度和屈光度
王卫群等^[37]	中国	193	6~14	－1.00~－6.00	12	0.01和0.02	单光眼镜	眼轴长度、屈光度、调节幅度及瞳孔直径
Brodstein等^[38]	美国	253	>5	－0.50~－1.25	108	1.0	不做任何治疗	眼轴长度和屈光度
Shih等^[39]	中国台湾	227	6~13	－0.50~－6.00	18	0.5	单光眼镜	眼轴长度和屈光度
Yi等^[40]	中国	132	7~12	－0.50~－2.00	12	1.0	安慰剂	眼轴长度、屈光度及视力
Wang等^[41]	中国	126	5~10	－0.50~－2.00	12	0.5	安慰剂	眼轴长度和屈光度
Chiang等^[42]	欧洲	706	6~16	≤－2.25	43	1.0	双焦眼镜	眼轴长度和屈光度

作者	地区	样本量	年龄	屈光度(D)	治疗时间(个月)	阿托品浓度(%)	对照组	结局指标
Yam等^[7]	中国香港	438	4~12	≤－1.00	12	0.05、0.025及0.01	安慰剂	眼轴长度、屈光度、调节幅度、视力及瞳孔直径
Chua等^[31]	新加坡	400	6~12	－1.00~－6.00	24	1.0	安慰剂	眼轴长度和屈光度
Chia等^[32]	新加坡	400	6~12	≤－2.00	24	0.5、0.1及0.01	安慰剂	眼轴长度、屈光度、调节幅度及视力
Chia等^[33]	新加坡	400	9~15	≤－2.50	24	0.01	安慰剂	眼轴长度、屈光力、瞳孔直径、调节幅度及视力
Sacchi等^[35]	欧洲	52	5~16	进展>0.50/年	12	0.01	安慰剂	眼轴长度、屈光度及视力
Wei等^[36]	中国	220	6~12	－1.00~－6.00	12	0.01	安慰剂	眼轴长度和屈光度
王卫群等^[37]	中国	193	6~14	－1.00~－6.00	12	0.01和0.02	单光眼镜	眼轴长度、屈光度、调节幅度及瞳孔直径
Brodstein等^[38]	美国	253	>5	－0.50~－1.25	108	1.0	不做任何治疗	眼轴长度和屈光度
Shih等^[39]	中国台湾	227	6~13	－0.50~－6.00	18	0.5	单光眼镜	眼轴长度和屈光度
Yi等^[40]	中国	132	7~12	－0.50~－2.00	12	1.0	安慰剂	眼轴长度、屈光度及视力
Wang等^[41]	中国	126	5~10	－0.50~－2.00	12	0.5	安慰剂	眼轴长度和屈光度
Chiang等^[42]	欧洲	706	6~16	≤－2.25	43	1.0	双焦眼镜	眼轴长度和屈光度

Please choose a citation manager

Content to export